Skip to Content
MilliporeSigma
All Photos(1)

Documents

F7307

Sigma-Aldrich

Fotemustine

≥98% (HPLC)

Synonym(s):

(+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate, Muphoran, Mustophorane, P-[1-[[[(2-Chloroethyl)nitrosoamino]carbonyl]amino]ethyl]-phosphonic acid diethyl ester, S 10036

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H19ClN3O5P
CAS Number:
92118-27-9
Molecular Weight:
315.69
MDL number:
MFCD00866278
UNSPSC Code:
12352200
PubChem Substance ID:
329799764

assay

≥98% (HPLC)

form

powder

storage condition

protect from light

color

light yellow

solubility

H2O: ≥1 mg/mL

originator

Servier

storage temp.

2-8°C

SMILES string

CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O

InChI

1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)

InChI key

YAKWPXVTIGTRJH-UHFFFAOYSA-N

Biochem/physiol Actions

Fotemustine is a third generation nitrosourea, chloroethylating agent used in the treatment of glioma and malignant melanoma.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H351

pcodes

P281

Hazard Classifications

Carc. 2

Storage Class

13 - Non Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xavier Durando et al.
Bulletin du cancer, 100(1), 23-28 (2012-08-15)
Brain metastases affect 37% of patients suffering from metastatic melanoma, and their prognosis remains poor, with an overall survival lower than six months. At the moment, there is no standard therapeutic strategy for management of melanoma brain metastases. In some
M Santoni et al.
Anticancer research, 32(3), 1099-1101 (2012-03-09)
Alkylating agents, such as temozolomide (TMZ) and fotemustine (FTM) are widely used in recurrent glioblastoma (GBM) regimes. Several strategies have been proposed to prevent resistance to these agents, by combining or sequencing them. We report the results of a pilot
Ipilimumab with fotemustine in metastatic melanoma.
Claus Garbe
The Lancet. Oncology, 13(9), 851-852 (2012-08-17)
Anna Maria Di Giacomo et al.
The Lancet. Oncology, 13(9), 879-886 (2012-08-17)
Ipilimumab improves survival of patients with metastatic melanoma, many of whom develop brain metastases. Chemotherapy-induced release of tumour antigens might amplify ipilimumab's antitumour activity. We aimed to investigate the efficacy and safety of ipilimumab plus fotemustine in patients with metastatic
Silvia Mangiacavalli et al.
American journal of hematology, 88(2), 102-106 (2012-12-12)
Since multiple myeloma (MM) is still not-curable, the management of relapse remains challenging. Given the known efficacy of alkylating agents in MM, we conducted a phase I/II study to test a new three drug combination in which Fotemustine (Muphoran), an
View All Related Papers

Articles

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service